Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon announces positive topline data from TEPEZZA® Phase 4 clinical trial in chronic/low clinical activity score (CAS) Thyroid Eye Disease (TED).